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ABSTRACT
Objective: To pilot and feasibility-test supervised final
year undergraduate pharmacy student-led medication
reviews for patients with diabetes to enable definitive
trial design.
Method: Third year pharmacy students were recruited
from one UK School of Pharmacy and trained to review
patient’s medical records and provide face-to-face
consultations under supervision while situated within
the patient’s medical practice. Patients with type 2
diabetes were recruited by postal invitation letter from
their medical practice and randomised via automated
system to intervention or usual care. Diabetes-related
clinical data, quality of life, patient reported beliefs,
adherence and satisfaction with medicines information
were collected with validated tools at baseline and
6 months postintervention. The process for collecting
resource utilisation data was tested. Stakeholder
meetings were held before and after intervention to
develop study design and learn from its
implementation. Recruitment and attrition rates were
determined plus the quality of the outcome data. Power
calculations for a definitive trial were performed on the
different outcome measures to identify the most
appropriate primary outcome measure.
Results: 792 patients were identified as eligible from
five medical practices. 133 (16.8%) were recruited and
randomised to control (n=66) or usual care (n=67). 32
students provided the complete intervention to 58
patients. Initial data analysis showed potential for
impact in the right direction for some outcomes
measured including glycated haemoglobin, quality of
life and patient satisfaction with information about
medicines. The intervention was found to be feasible
and acceptable to patients. The pilot and feasibility
study enabled the design of a future full randomised
controlled trial.
Conclusions: Student and patient recruitment are
possible. The intervention was well received and
demonstrated some potential benefits. While the
intervention was relatively inexpensive and provided an
experiential learning opportunity for pharmacy students,
its cost-effectiveness remains to be determined.
Trial registration number: ISRCTN26445805;
Results.
INTRODUCTION
It is estimated that preventable harm from
medicines costs the National Health Service
(NHS) in England £750 million per year.1 A
systematic review in 2009, based on UK
research, estimated that only between 4%
and 21% of patients achieved the optimum
beneﬁt from their medication.2 A systematic
review of publications between 1966 and
1999 reported the prevalence of preventable
drug-related admissions to hospital as 4.3%.3
Additionally, patients not taking their medi-
cines as agreed with the prescriber has been
reported to cost the UK NHS an estimated
half a billion pounds a year.4 Consequently,
interventions designed to reduce adverse
drug events and improve patient medicines-
taking behaviours are required.
Medication review (MR) has been deﬁned
as ‘a structured, critical examination of a
patient’s medicines with the objective of
Strengths and limitations of this study
▪ The study followed recommendations published
by the Medical Research Council for implementa-
tion of feasibility and pilot studies.
▪ The intervention was developed with significant
stakeholder involvement, a range of primary
outcome measures were tested for suitability and
the process for collecting resource utilisation
data was identified.
▪ Self-selection bias was found within those stu-
dents who consented to participate.
▪ The trial was unblinded with the service provi-
ders, patients and research all aware of group
allocation and intervention content.
▪ The large number of statistical tests carried out
creates the possibility that findings could be
false positives and as this was a pilot and feasi-
bility study which, therefore, used a low power
we could potentially fail to detect small to mod-
erate sized effects.
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reaching an agreement with the patient about treat-
ment, optimising the impact of medicines, minimising
the number of medication-related problems in addition
to reducing waste.5 MR in the UK was described as oper-
ating at four different levels,5 with the key component of
level 3 medication reviews being the involvement of the
patient while accessing medical records.
Pharmacist-led medication reviews have been shown to
reduce costs associated with unnecessary prescribing of
medication while potentially providing patient beneﬁt.6
However, recent UK-based research utilising pharmacists
to provide medication reviews found a counter-intuitive
increase in hospitalisation,7 with one partial explanation
being the didactic nature of the pharmacist communica-
tion.8 9 Effective communication skills are necessary to
improve patient behaviours in terms of lifestyle10 and
medication taking.11 Consequently, models of consultation
behaviour have been developed and are commonly used
within the education of healthcare professionals.12 13
While UK pharmacy graduates develop expertise in
the pharmacology and therapeutics of medicines, under-
graduate training currently lacks signiﬁcant patient
contact. This provides limited opportunities for the
development of clinical and communication skills
during training.14 In contrast, medical students routinely
work with patients during their undergraduate training15
and undergraduate students within Schools of Dentistry
and Optometry provide services to patients under the
supervision of clinical tutors to improve both their clin-
ical and communication skills.16 17
Involvement of pharmacy students in the provision of
healthcare services in other countries has been
reported18 19 with very good prescriber acceptance of
student recommendations.20 However, pharmacy student
provision of medication review to patients in the UK, with
the dual aims of demonstrating patient beneﬁt and
improving student communication and clinical skills, has
not been tested. For new models of care to be adopted, it
is necessary to demonstrate that they are likely to be cost-
effective. There is currently no evidence of this for the pro-
vision of pharmacy student-led medication review services.
Two and a half million of the UK population currently
have type 2 diabetes with an estimated direct cost to the
health system of £8.8 billion/annum.21 Pharmacist-led
medication reviews for patients with diabetes have
demonstrated signiﬁcant reductions in blood pres-
sure22 23 and glycated haemoglobin (HbA1c),24 25 both
of which are necessary to reduce long-term morbidity.26
Approximately 60% of patients are achieving the target
HbA1c below 7.5% (59 mmol/mol). 27 Owing to the
availability of clearly deﬁned national treatment guide-
lines28–30 and increasing numbers of patients with type 2
diabetes, medication review for patients with diabetes is
a health service which pharmacy students may be able to
usefully provide.
A pilot and feasibility study was, therefore, undertaken
in line with national guidance for the evaluation of
complex interventions31 to determine recruitment and
attrition rates for students and patients; describe the suit-
ability of using student volunteers; test data collection for
a future cost-effectiveness analysis; describe the potential
effects of the intervention; identify the most suitable
primary outcome measure; and estimate variance around
this to enable a future trial to be effectively powered.
METHOD
ISRCTN No 26445805 was obtained retrospectively rather
than prospectively due to misinterpretation of an
National Institute for Health Research (NIHR) email
stating that “NIHR Clinical Research Network (CRN)
Coordinating centre had developed a process which
enables automatic registration of all new NIHR Clinical
Research Network Portfolio studies via the Portfolio.” We
did not notice that they provided details of ISRCTN regis-
tration via UKCRN Portfolio, later in the same email.
Student recruitment and preparation
All 84 third year pharmacy students from one UK school
of pharmacy were invited to participate in June 2011.
The intervention was timetabled to occur during the
ﬁnal year (fourth) of their undergraduate studies.
Informed consent was obtained from students agreeing
to participate. A reserve list was created and used to
resolve any anticipated drop-out caused by the add-
itional workload created by the study within the stu-
dents’ ﬁnal year.
Standard education process already included basic
training in consultation skills, data governance and
observation of a primary care doctor in practice. In add-
ition, participating ‘study students’ undertook four
half-day training sessions comprising the following:
▸ Use of medical practice information systems using
‘dummy’ patient records;
▸ Revision of ‘pharmaceutical care planning’ using a
care plan designed to enable recording of patient
details and also to provide a guide to their
consultations;
▸ A consultation skills workshop which included utilis-
ing dummy primary care patient records and training
in basic behaviour change counselling;
▸ Two medicines-related consultations with pre-
prepared and scripted professional role-play actor
‘patients’, following which individual and group feed-
back was provided.
All student activities connected with this trial were
undertaken outside the university curriculum, with stu-
dents donating their time. Student preparative training
was undertaken at the University of East Anglia, apart
from training in the use of computerised medical
records which was provided by NHS Norfolk and
Waveney.
Examination results for students (both participating
and non-participating) were obtained at the end of year
three (ie, shortly after recruitment) to identify potential
student self-selection bias.
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Medical practice and patient recruitment
Five Norfolk-based medical practices were purposively
recruited by NHS Norfolk and Waveney. The inclusion
criteria were:
▸ Pharmacist working as a prescribing advisor within
the practice;
▸ Using the SystmOne IT medical record system;
▸ Over 200 patients registered with type 2 diabetes.
Presence of a pharmacist was required to enable
student supervision; the same system facilitate student
training. A target number of patients was required to
increase the opportunity for meeting recruitment
targets.
Patient recruitment
Patients in each medical practice who met the following
criteria were posted a letter from the practice asking
them to participate in the study:
Inclusion criteria
Prescribed non-insulin medication for type 2 diabetes
mellitus for at least 2 years to increase likelihood that
therapy is stabilised.
Exclusion criteria
▸ Deemed unsuitable for inclusion in the trial by their
medical practitioner for any reason;
▸ Enrolled into other clinical trials;
▸ Diagnosed with a terminal illness.
All recruited patients were randomised to intervention
or control (standard care) using an automated random-
isation system, developed and controlled by the clinical
trials unit, which ensured concealed allocation.
Randomisation was undertaken in blocks of four to
maximise equality of group size. All researchers and clin-
ical staff involved with generating outcome date were
blind to participant allocation.
As a pilot study it was decided to test a number of poten-
tial primary outcome measures, with results enabling a
decision as to which measure to use in a future study:
▸ HbA1c;
▸ Blood pressure;
▸ Lipid proﬁle.
Secondary outcome measures were the effect on:
▸ Health-related quality of life (EQ-5D);
▸ Satisfaction with information about medicines
(SIMS);32
▸ Medication adherence (MARS);33
▸ Patient’s beliefs about medicines (The Beliefs and
Medicines Questionnaire);34
▸ Diabetes Treatment Satisfaction Questionnaire
(DTSQ).35
Level 2 medication reviews were undertaken by stu-
dents between November 2011 and February 2012 while
student-led patient consultations (level 3 medication
review) took place between December 2011 and March
2012.
Sample size justification
As a pilot study it was not appropriate to power the
study. Consequently we determined the likely precision
of the study for estimating the effect of the intervention
on the continuous end points by estimating the
expected value of the half-width of the 95% CI around
the difference in means between the intervention and
control groups. Assuming 80 patients in each group and
a SD of 1.5% in the primary outcome variable of HbA1c
then the estimate from this pilot study of the effect of
the intervention on this end point would be within 0.5%
of its ‘true’ value. An observed difference in group
means >0.5% (eg, HbA1c 7% compared to 7.5%) would
be statistically signiﬁcant.
From each of the ﬁve practices, 32 patients were,
therefore, required providing 160 in total (80 in each of
intervention and control arms). It was planned that each
student would be allocated two patients in the interven-
tion arm for review and consequently 40 students were
required.
Baseline data
Both intervention and control participants were posted
a questionnaire comprising the secondary outcome mea-
sures, which included an additional question asking
whether they used a medicines compliance aid.
The patient notes within the medical practice were inves-
tigated to obtain:
▸ Demographic data;
▸ Most recent results prior to recruitment for HbA1c,
blood pressure and lipid proﬁle;
▸ Medication utilisation (cost of all prescriptions issued
for each patient for a baseline period of 3 months
prior to intervention and 6 months postintervention;
▸ NHS resource utilisation calculated as cost (using
standard NHS staff cost) of all NHS contact for a
baseline period of 3 months prior to intervention and
6 months post-intervention in primary and secondary
care.
The last two items were included to determine the
feasibility of collecting data for a future cost-effectiveness
analysis within a randomised controlled trial.
Intervention
At the patient’s medical practice, students were rando-
mised to work in pairs. This provided additional support
and shared learning in addition to the wider clinical
experience provided by access to additional patient
records. Each pair, therefore, worked to undertake level
2 medication reviews for four intervention patients
under the supervision of a PCT pharmacist. Students
compared prescribing with national guidance28–30 and
created individualised pharmaceutical care plans (PCP)
on a predeﬁned pro forma.
PCPs included demographics, allergies, special needs,
lifestyle for example, diet and smoking status, relevant
medical history, medication adherence, pharmacy use,
current prescribed medication, over the counter, herbal
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and homeopathic preparation use and any care issues
identiﬁed. After discussion and agreement with the
supervising pharmacist, care issues identiﬁed were fed
back on a custom-designed form, to either the patient’s
specialist diabetes nurse or medical practitioner who
then decided on the ﬁnal action.
Patients were then offered a range of ﬂexible dates
and times, to maximise participation of a meeting
between each student and an individual patient.
The presence of a supervising pharmacist was ensured
during all student-led medication reviews to ensure com-
petence. The consultation (level 3 medication review)
took place at the patient’s medical practice and was
separated by at least 2 weeks from the level 2 review to
enable the doctor or nurse to rectify or question any
problems identiﬁed by students, prior to the subsequent
student-led consultation. As planned in the protocol,
each student provided two patient consultations which
had no time limit imposed on their duration.
Follow-up
Six months postintervention, a questionnaire was posted
to both intervention and control participants. The
questionnaire was identical to the baseline version but
with an additional question regarding frequency of com-
munity pharmacy service utilisation. Intervention partici-
pants were also asked to report any change in utilisation
of community pharmacists following the student consult-
ation to identify any change in attitude to or view of
community pharmacists. The same data as baseline were
collected from the medical practice, with HbA1c, blood
pressure and lipid proﬁle collected at 6 months postin-
tervention with a cut-off point of 1 year; and medication
and resource utilisation for the 6-month period
postintervention.
Stakeholder meetings
Stakeholder meetings were held with patients, students,
primary care pharmacists and medical practice staff both
before and after the intervention. Interested individuals
were recruited prior to the study’s implementation to
inform the design of the intervention and trial, while
study participants were recruited postintervention to
learn from their experiences. All meetings were
recorded and transcribed verbatim.
Data analysis
The variance in the difference between each primary or
coprimary outcome measure between groups was
Figure 2 Consort diagram for student participants.Figure 1 Consort diagram for patient recruitment.
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undertaken on an intention-to-treat basis using inde-
pendent t test and Mann-Whitney U test. The patient
recruitment rate and the medicine-related consultation
uptake rate were both determined. SPSS V.22 was used
for analysis.
Stakeholder meeting analysis
Simple content analysis which proceeded to identify all
themes, as recognised by the researcher, was undertaken
for development meetings with the main learning points
recorded for action as appropriate. Review meeting ana-
lysis followed the general principles of the framework
approach.36 There was no independent analysis of the
data. Nvivo 10 was used to facilitate analysis.
Health economics analysis
As a pilot study we report completion rates for resource
use items and the EQ-5D. Additionally, unit costs37 were
extracted in order to enable the cost of the intervention
to be estimated.
RESULTS
All ﬁve medical practices which responded to recruit-
ment requests were consented to join the study.
Figure 1 summarises the patient recruitment process
which achieved a 16.8% consent rate. Recruitment rates
within the ﬁve medical practices were 17.2%, 19.6%,
20.1%, 18.5% and 9.4%. The research team received a
number of contacts from patients who had been
approached by the medical practice with a 9.4%
response rate to complain that they had received recruit-
ment letters without stamps. The ﬁrst two practices
recruited in time to enable students to complete medica-
tion reviews before Christmas 2011. The other three
practices recruited later resulting in student-led medica-
tion reviews in one practice being undertaken in March
2012. Of the 67 patients randomised to intervention,
91% remained in the study prior to the student-led
medication review with 100% of those agreeing to an
appointment with a student for a consultation. Of these,
three (4.9%) failed to attend the consultation.
Figure 2 provides a summary of the ﬂow of students at
each stage of the study. Of the 47 students who volun-
teered and completed a consent form, 12.75% were
male. The ﬁrst 40 students volunteering were recruited
with the remaining seven forming the reserve list used if
recruited students left the study. Patient consultations
were undertaken by 32 of the 47 (68%); however, of
these six only undertook one consultation due to
patient numbers. Mean (SD) examination scores at end
of year three (at recruitment) for participating and non-
participating students were 62.80 (7.91) and 58.91
(7.98), respectively. Academic performance of participat-
ing students was signiﬁcantly better than non-
Table 1 Comparison of patient demographics at baseline
Characteristic Measure
Usual range or
ideal figure
Intervention
patients (n=67)
Control patients
(n=66)
Age Mean (SD) NA 69.18 (10.46) 68.31 (9.46)
Male Number (%)t NA 45 (68%) 38 (58.5%)
HbA1c mmol/mol Mean (SD) 48 56.81 (11.12) 59.71 (13.92)
Total cholesterol mmol/L Mean (SD) <4.0 4.14 (0.99) 4.19 (0.91)
Blood pressure mm Hg
Systolic Mean (SD) 140 132.48 (11.98) 131.65 (10.90)
Diastolic Mean (SD) 80 73.22 (8.15) 72.13 (9.54)
Euroqol VAS scale Median (IQ) NA (n=45)
80 (70, 90)
(n=48)
80 (70, 90)
EQ-5D-5L
Mean (SD) NA
(n=43)
0.766 (0.168)
(n=48)
0.736 (0.184)
SIMS (n=43) (n=47)
Total Median (IQ) 17 12 (7, 17) 12 (8, 15.5)
Action and use Median (IQ) 9 7 (4.75, 9) 7 (5, 9)
Potential problems Median (IQ) 8 5.5 (2.25, 8) 5 (2, 8)
BMQ (n=43) (n=47)
Necessity Median (IQ) 5 18 (16, 21) 19 (17, 21)
Concerns Median (IQ) 5 11.5 (10, 14) 13 (10, 16)
MARS (n=43) (n=47)
Median (IQ) 25 24 (23, 24) 24 (23, 24)
DTSQ (n=45) (n=48)
Treatment satisfaction Median (IQ) 36 30 (26, 35) 31 (26, 34)
Problem-hyperglycaemia Median (IQ) 0 1 (0, 3) 2 (0, 3)
Problem-hypoglycaemia Median (IQ)s 0 0 (0, 1) 0 (0, 3)
Using a medicine compliance aid (MCA) Number (%) NA 44 (47.7%) 48 (43.8%)
DTSQ, Diabetes Treatment Satisfaction Questionnaire; Euroqol VAS scale, Euroqol visual analogue scale; HbA1c, glycated haemoglobin;
MARS, medication adherence; SIMS, satisfaction with information about medicines; NA, not applicable.
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participating students at the point of recruitment
(p<0.05, independent samples t test).
Table 1 presents baseline, demographic, clinical and
questionnaire data for control and intervention patients.
The data indicate that randomisation resulted in reason-
ably comparable groups, although the wide SD demon-
strates considerable numbers of patients in each group
were failing to achieve clinical targets.
Table 2 presents 6 months postintervention data
including clinical data and results of patient-completed
questionnaires. Questionnaire responses were received
from 94 (70.7%) of the 133 patients with non-
respondents and omission of responses to individual
questions being comparable across the two groups.
Signiﬁcant differences between intervention and control
groups were only observed for change in quality of life
and some elements of SIMS.
Figure 3 illustrates a comparison of the SIMS question-
naire responses for intervention and control patients at
follow-up (6 months postintervention). It demonstrates
that patients in the intervention group were signiﬁcantly
more satisﬁed with ﬁve parameters (one action and
usage, four concerns) out of the 17 questions.
Control n=34 Intervention n=36.
Twenty-ﬁve (55.5%) patients who had met a student
for a level 3 medication review and answering this ques-
tion agreed or strongly agreed that they were far more
likely to speak to a pharmacist about their medicines or
their health following the medication review, while 11
(24.5%) were unsure.
It was calculated that for a full randomised controlled
trial (RCT) to demonstrate an effect on HbA1c, 159
patients would be required in each arm of control and
intervention to demonstrate 80% power with 214
patients per group to demonstrate a 90% power. Data
utilised for sample size analysis are presented in table 3.
Health economics analysis
The mean per participant cost of the intervention was
£164.41; table 4 provides a breakdown of the component
parts. We used different versions of the EQ-5D (the ﬁve-
level version38 at baseline and the three-level39 at follow-up)
Table 2 Comparison of patient outcomes post-intervention
Characteristic Measure
Intervention
(n=67) Control (n=66)
p
Value
Mean (95% CI) difference OR
Median difference
HbA1c mmol/mol Number (%) 59 (88.1) 59 (89.4)
Mean (SD) 56.32 (11.5) 59.68 (13.2) 0.14# −3.36 (−7.781 to 1.11)
Total cholesterol mmol/L Number (%) 61 (91.0) 53 (80.3)
Mean (SD) 4.22 (1.0) 4.01 (0.8) 0.47# 0.13 (−0.23 to 0.5)
Blood pressure mm Hg Number (%) 61 (91) 60 (90.9)
Systolic Mean (SD) 132.26 (12.9) 127.98 (11.9) 0.06# 4.35 (−0.15 to 8.84)
Diastolic Mean (SD) 73.38 (6.8) 70.97 (9.5) 0.11# 2.41 (−0.52 to 5.34)
Euroqol VAS Number (%) 51 (76.1) 48 (72.7)
Median (IQ) 80 (70, 85) 72.5 (61.3, 85) 0.182* 7.75
Change from baseline Number (%) 37 (55.2) 40 (60.6)
Mean (SD) +2.00 (8.73) −6.24 (18.28) 0.015# 8.24 (1.65 to 14.8)
EQ-5D-3L Number (%) 51 (76) 46 (69.7)
Mean (SD) 0.768 (0.224) 0.736 (0.233) 0.49 0.031 (−0.06 to 0.123)
Change from baseline Number (%) 35 (52.2) 38 (57.6)
Mean (SD) 0.048 (0.133) −0.003 (0.134) 0.103# 0.052 (−0.011 to 0.114)
SIMS Number (%) 50 (74.6) 47 (71.2)
Total Median (IQ) 14 (9.2, 17) 10 (6, 15) 0.073* 4
Action and usage Median(IQ) 8 (7, 9) 8 (6, 9) 0.078* 0
Potential problems Median (IQ) 3 (5, 8) 2 (3.5, 7.7) 0.037* 1
BMQ Number (%) 48 (71.6) 49 (74.2)
Necessity Median (IQ) 20 (18, 22.5) 20 (19, 22) 0.925* 0
Concerns Median (IQ) 14 (12, 16) 14 (12, 15) 0.825* 0
MARS Number (%) 50 (74.6) 48 (72.7)
Median (IQ) 24 (23, 2) 24 (23, 2) 0.843* 0
DTSQ Number (%) 49 (73.1) 48 (72.7)
Treatment satisfaction Median (IQ) 32 (26.5, 35) 30.5 (27.7, 33.2) 0.413* 1.5
Problem-hyperglycaemia Median (IQ) 1 (0, 3) 1 (0, 2) 0.360* 0
Problem-hypoglycaemia Median (IQ) 1 (0, 1) 0 (0, 2) 0.929* 1
Using a medicine
compliance aid (MCA)
Number (%) 50 (74.6) 46 (69.7)
Number (%) 23 (46.0) 25 (54.3) 0.540$
The test used to identify the p value is indicated by # Independent samples t test, * Mann Whitney U, $ Fisher’s exact test.
BMQ, Beliefs about medicines questionnaire; DTSQ, Diabetes Treatment Satisfaction Questionnaire; Euroqol VAS scale, Euroqol visual
analogue scale; HbA1c, glycated haemoglobin; MARS, medication adherence; SIMS, satisfaction with information about medicines.
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to assess whether completion rates differed according to
the number of levels. The response rates were slightly
higher for the EQ-5D-3 L and the mean change in EQ-5D
score was slightly higher for the intervention arm (see
tables 1 and 2). Complete cost and effect data were avail-
able for 72 participants (54.1% of the sample).
Stakeholder meetings
All stakeholder groups supported the testing of the idea.
There was agreement that student-led consultations
should take place at the medical practice of each patient
rather than at the university, should not be time-limited
and should be supervised. Postintervention stakeholder
groups agreed that the experience had been generally
positive, had provided both student and patient beneﬁt
and raised awareness of the role of pharmacists.
Table 4 provides a summary of the main points
learned from the stakeholder meetings before and after
intervention where opinions did not concur across
groups.
Table 5 presents identiﬁed intervention costs. It can
be seen that there are signiﬁcant ﬁxed costs associated
with setting up the service: the mean cost per partici-
pant is relatively small.
DISCUSSION
This pilot study has demonstrated the acceptability and
practicality of pharmacy students providing full medica-
tion review to patients with type 2 diabetes under super-
vision. All stakeholder groups displayed support for the
concept, with patients also displaying a willingness to
participate in a subsequent RCT. Medical practices were
purposively selected, and no problems were experienced
with patient recruitment, though recruitment rates were
relatively low (17%) and may display a better response
rate without postal issues experienced at one medical
practice. Nevertheless, future recruitment for a full RCT
would be possible and may display a better response
without postal issues experienced at one medical prac-
tice. Importantly, there was also a very low patient
dropout rate (<10%). The logistics of patients having to
attend an additional clinic within the intervention group
resulted in the loss of patients due to illness and
bereavement which were unavoidable losses to the study
and two due to forgetting to attend. A longer period to
allow for rebooking and reminders closer to the time
of the appointment may have prevented these drop-outs.
A longer time period to allow for rebooking and remin-
ders closer to the appointment may have helped but
would increase the costs. Potential patient beneﬁt was
also identiﬁed within some of the outcome measures.
The results, therefore, provide evidence that within an
RCT, sufﬁcient patients could be expected to agree to
attend for a medication-related consultation.
As this was a pilot study, and had small participant
numbers we did not expect to demonstrate signiﬁcant
effects in our outcome measures. Students were volun-
teers and may not represent a full population of under-
graduate pharmacy students. All participating medical
practices were requested to start recruitment at the same
Figure 3 Provides a comparison of the satisfaction with
information about medicines (SIMS) questionnaire responses
for intervention and control patients at follow-up (6-month
postintervention). It demonstrates that patients in the
intervention group were significantly more satisfied with five
parameters (one action and usage, four concerns) of the 17
questions (control n= 34; intervention n= 36).
Table 3 Data used to calculate sample size
Output
measure
Standard error of
mean difference #
Standard deviation
of mean difference
Clinically
important
difference
Unit of
clinical
measure
Number of patients
required in each
group
HbA1c 2.28 17.5 5.5 mmol/mol 159
Systolic blood
pressure
2.27 12.47 3.3 mm Hg 224
Patients were included in the intention to treat analysis even if they did not complete questionnaires.
HbA1c, glycated haemoglobin.
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time; however, results demonstrate patient recruitment
proceeding over a period of greater than 4 months,
resulting in logistical issues within the project. Ethical
reasons required recruitment to be initiated via the
medical practices, but results suggest that closer commu-
nication and support may be required between the
researcher and medical practices to facilitate earlier
recruitment. Written appointment information may aid
patient attendance and prevent the small number of
patients failing to attend due to forgetfulness. The large
number of statistical tests carried out, increases the likeli-
hood of false positives. Conversely as a pilot and feasibil-
ity study with limited sample size there is an increased
likelihood of false negatives.
While student willingness to participate was high, pres-
sures of concurrent timetabled course work and a lack
of conﬁdence in ability to perform the consultation
resulted in signiﬁcant drop out during the progress of
the study. Integration of the service into the curriculum
did not result in drop out from similar non-UK
studies.18 19 Participating students were volunteers and,
therefore, self-selecting. Given that they were, on
average, academically superior when compared to non-
participating students, they would potentially have per-
formed better than non-participants during a
student-led consultation. Most studies do not mention
this effect and any future study utilising volunteer stu-
dents should recognise and allow for it.18 40–43 The edu-
cational element of this study was not considered within
this paper as this will form the focus of a future submis-
sion. The quality of medicines information given to
patients affects individual’s perception of whether it has
met their needs and if they are satisﬁed with the infor-
mation provided.32 It is reasonable to speculate that
repetition of information over a period of years to
patients with a long-term condition would have resulted
in a greater understanding of and, therefore, satisfaction
with information about their medicines. This may have
reduced the ability to improve scores for many of the
individual questions. While higher scores for SIMS is
theoretically a predictor for better adherence (MARS)32
no improvement in adherence was observed. The rela-
tively high proportion of patients who reported using
medication compliance aids prior to the intervention
might have reduced the potential for the intervention to
further improve adherence. Adherence, beliefs about
Table 4 Main points learned from stakeholder meetings
Location Patients Students
Preintervention Care plan or protocol for use during consultation
Current unmet information need
Ensure paperwork is easily comprehensible
Ensure students are confident
Ensure preparative training
Supervision of student essential
Students must admit knowledge gaps
Transport should be provided
Group feedback on their performance where
possible
Postintervention Real-life teaching required
Willingness to participate in the future
Recruitment—avoid Christmas and mail best method
Confirmed GP practice best location
Praise (not universal) for students’ consultation skills
Request use of email within consent and utilise for
appointments and reminders where agreed
Preparative training—some elements and timing
criticised. Role play most effective
Supervisor feedback useful
Level 2 medication effective preparation for
consultation
Wanted consultations with more patients
Difficulties completing study outside course
Educational benefit obtained
Preferred to Objective Structured Clinical
Examinations (OSCEs) or role play
Location Primary care pharmacists Medical practice staff
Preintervention Care plan or protocol for use during consultation
Ensure preparative training
Students access medical record prior to consultation
Care plan or protocol for use during consultation
Ensure preparative training
Students access medical record prior to
consultation
Ensure students do not contradict nurse advice
Postintervention Role play good—in ‘protected’ environment
Supervisor feedback useful
Enjoyed participation
Improved their own continuing professional
development (CPD)
Confirmed that GP practice best location
Feedback after each consultation improved
performance
Consultation must be recorded in patient’s records
Need protected time for students to feedback
recommendations
GP, general practitioner.
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medication, satisfaction with diabetes treatment and
quality of life all displayed a change in the direction
which favours the intervention, all of which support a
full study going ahead. No evidence is available to deﬁni-
tively explain the change in blood pressure seen in the
control group and reasons for this would only be specu-
lative, but it may simply have been a chance ﬁnding. It
may be more appropriate to focus the intervention on
those patients with the greatest HbA1c or the lowest
reported satisfaction with information or adherence,
however this may affect the recruitment rate and would
require careful consideration prior to implementation in
a full RCT if using the results from this study for it basis.
Results demonstrate that HbA1c would appear to be
a sensible primary outcome measure for a future study.
A sample size of 214 patients per group (428 in total)
would be required to demonstrate a 90% power. This
would equate to 107 students (two patient consultations
per student), which is achievable within a full RCT
undertaken over more than one school of pharmacy.
However, recent National Institute for Health and Care
Excellence (NICE) guidance recommends the utilisation
of a cardiac risk measure (QRisk2)44–46 which represents
a compilation of clinical data. Insufﬁcient data is avail-
able to calculate a sample size for QRisk2, therefore, the
pragmatic decision would be to utilise a primary
outcome measure of HbA1c with QRisk2 possibly uti-
lised as a secondary outcome measure.
Implementation of student activity described within
this study is in line with current government agenda for
pharmacy education.47 Evidence does not exist in the
UK to support the training of undergraduate pharmacy
students when undertaking activities with real patients,
although examples exist outside the UK.18 19 42 This
study does not provide deﬁnitive evidence for this, but
does provide support for a future deﬁnitive RCT to test
this hypothesis.
With a known patient recruitment rate and low
dropout rate this demonstrates that if utilising the same
protocol for a future RCT, not only can sufﬁcient
numbers of patients be expected to be recruited and
retained. Medical practices were chosen because they all
used the same software system for electronic medical
records, as this would facilitate student training, however,
utilising additional systems would increase the number of
general practitioner practices available for recruitment.
Table 5 Resource utilisation costs
Component part Resources costed (unit cost), participant costing
Total
cost (£)
Mean cost as £
per participant
Development of training plan 1 h meeting for 4 people (3 pharmacists @ £50 per
hour*; 1 RA @£25 per hour†)
175.00 2.61
Development of background
material
Podcasts on diabetes and cardiovascular and
communication skills. 1.5 h of pharmacist time @ £50
per hour*;
75.00 1.12
IT workshop 1 day preparation (RA @£25 per hour†); IT Dept. costs
(room and trainer for 4*0.5 day sessions—£600 flat fee);
supervision and assistance with training (2 days of
pharmacist time @£50 per hour*)
887.50 13.25
Care planning workshop Preparation (1 h RA @£25 per hour† and 1 h
pharmacist @ £50 per hour); delivery (3 h RA time @
£25 per hour† and 3 h pharmacist time @ £50 per hour)
300.00 4.48
Communication/consultation
skills with motivational
interviewing
Preparation (2 h pharmacist time @£50 per hour);
delivery (3 h RA time @£25 per hour† and 3 h
pharmacist time @ £50 per hour)
325.00 4.85
Role play workshop Preparation (9.5 h RA time @£25 per hour† and 3 days
of pharmacist time @£50 per hour) Per session: 2 h of
consultation/MR practice (2 h RA time @£25 per hour†
and 2 h pharmacist time @ £50 per hour) and 1 h of GP
feedback (1 h RA time @£25 per hour† and 1 h GP time
@ £118 per hour). 7 sessions (6 students per session).
3238.50 48.34
Level 2 review Based in general practice, look at medical records and
create care plans. Per session: 3 hours of pharmacist
time (@£50 per hour*). Specialist nurse attended for the
last hour (@£52 per hour). 13 sessions held (3 students
per group)
2626.00 39.19
Level 3 review 1 h per patient at general practice (pharmacist @£50
per hour*). Specialist nurse attended for 15 min (@£52
per hour). Held with 54 patients
3402.00 50.78
*Taken from Curtis.37
†Estimate based on within study costs.
GP, general practitioner; IT, information technology; MR, medication review.
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Changes may be warranted to patient selection criteria,
as recruitment of patients who are not yet clinically stabi-
lised may be more receptive to information regarding
their medicines. NICE CG6644 recommends a blood pres-
sure target level of <140/80 mm Hg for most people with
type 2 diabetes, and <130/80 mm Hg for those at more
particular risk. The latter group includes people with
raised albumin excretion rate (microalbuminuria or
worse), estimated glomerular ﬁltration rate <60 mL/
min/1.73 m2, those with retinopathy, and those with
prior stroke or transient ischaemic attack. Data to enable
such differentiation was not obtained within the pilot
study and should be included in the design of a future
deﬁnitive RCT. Provision of opportunities for students to
undertake more than two consultations in future studies
may demonstrate further student and patient beneﬁt.
Results provide evidence that within an RCT, sufﬁcient
patients could be expected to agree to attend for a
medication-related consultation. Written appointment
information may aid patient attendance and prevent the
small number of patients failing to attend due to forget-
fulness. Where acceptable to participants, email appoint-
ments and reminders for consultations may be effective.
This pilot study conﬁrms that the data required for evalu-
ation of health economics is possible in a RCT. To
address the rate of availability of cost and effect data, in
any future study we would make every effort to ensure
that baseline measures are completed prior to randomisa-
tion. The design of a deﬁnitive trial should ensure that
medical practitioners receive feedback from the students
to potentially increase the effectiveness of the interven-
tion. The results from this study display good generalisa-
tion, as recruitment and the intervention followed
existing scenarios where possible, however student aca-
demic ability may affect interpretation. Results support a
future RCT as the intervention appeared to have the
potential to improve blood glucose sugar control, quality
of life and medicine information and these ﬁndings need
more formal testing.
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